Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Incannex Healthcare Ltd ADR

Healthcare US IXHL

3.06USD
0.01(0.33%)

Last update at 2026-06-03T20:24:00Z

Day Range

3.003.12
LowHigh

52 Week Range

0.8012.68
LowHigh

Fundamentals

  • Previous Close 3.05
  • Market Cap45.39M
  • Volume172774
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.21225M
  • Revenue TTM0.66M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 1.01M
  • Diluted EPS TTM-0.88

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -19.97956M -14.90391M -8.16359M -3.92928M -2.86972M
Minority interest - - - - -
Net income -19.97956M -15.02599M -8.16091M -4.65655M -2.71840M
Selling general administrative 10.01M 7.43M 3.44M 1.78M 1.90M
Selling and marketing expenses 1.85M 2.75M 1.14M 0.41M 0.70M
Gross profit 0.00000M -0.00634M 0.99M 0.15M 0.60M
Reconciled depreciation 0.13M 0.00000M - 0.04M 0.04M
Ebit -20.34232M -14.77555M -8.23934M -4.18300M -2.78466M
Ebitda -20.21138M -14.64093M -8.23934M -4.14645M -2.74277M
Depreciation and amortization 0.13M 0.13M 0.08M 0.04M 0.04M
Non operating income net other - - - - -
Operating income -20.34232M -14.77555M -8.23934M -4.18300M -2.78466M
Other operating expenses 20.34M 14.78M 10.14M 4.75M 3.97M
Interest expense - 0.00627M 0.00268M 0.00455M 0.09M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -0.15132M
Interest income 0.36M 0.00912M 0.00268M 0.00455M 0.00163M
Net interest income 0.36M 0.00912M 0.00268M 0.00455M -0.08343M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.12M -0.00268M 0.73M -0.15132M
Total revenue 0.00000M 0.00000M 1.90M 0.60M 1.18M
Total operating expenses 20.34M 14.77M 9.22M 4.30M 3.38M
Cost of revenue 0.00000M 0.00634M 0.91M 0.45M 0.58M
Total other income expense net 0.36M -0.12835M 0.08M 0.25M -0.08507M
Discontinued operations - - - -0.76835M -1.29220M
Net income from continuing ops -19.97956M -21.66551M -8.16359M -3.92928M -2.71840M
Net income applicable to common shares -19.97956M -14.90391M -11.37280M -4.69764M -2.71840M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 88.59M 37.88M 9.33M 4.24M 0.52M
Intangible assets 52.72M - - - 0.05M
Earning assets - - - - -
Other current assets 1.04M 0.06M 0.04M 0.03M 0.03M
Total liab 4.46M 2.01M 0.76M 1.07M 0.94M
Total stockholder equity 84.13M 35.87M 8.57M 3.16M -0.41718M
Deferred long term liab - - - - -
Other current liab 0.97M 0.71M 0.52M 0.48M 0.35M
Common stock 150.84M 86.59M 45.94M 34.19M 26.95M
Capital stock 150.84M 125.87M 45.94M 34.19M 26.95M
Retained earnings -78.77447M -58.79491M -40.68179M -32.51820M -27.82057M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 33.36M 37.50M 9.12M 3.60M 0.09M
Cash and equivalents - - - - -
Total current liabilities 3.85M 2.01M 0.76M 1.07M 0.94M
Current deferred revenue - - - - 0.15M
Net debt -32.57648M -37.50093M -9.12362M -3.60339M -0.02833M
Short term debt 0.17M - - - 0.07M
Short long term debt - - - - 0.07M
Short long term debt total 0.79M - - - 0.07M
Other stockholder equity 12.06M 8.08M - - -
Property plant equipment 1.19M - - - 0.09M
Total current assets 34.69M 37.88M 9.33M 4.24M 0.38M
Long term investments - - - - -
Net tangible assets 31.41M 35.87M 8.57M 3.16M -0.46656M
Short term investments - - - - -
Net receivables 0.39M 0.32M 0.17M 0.41M 0.10M
Long term debt - - - - -
Inventory -0.10001M - - 0.18M 0.15M
Accounts payable 2.71M 1.30M 0.23M 0.59M 0.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 12.06M - 3.32M 1.49M 0.45M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 53.90M 0.00000M 0.00000M 0.00000M 0.13M
Capital lease obligations 0.79M - - - -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.47687M 0.00000M 0.03M 0.01M -0.02444M
Change to liabilities 1.56M 1.11M -0.29131M 0.46M -0.25745M
Total cashflows from investing activities -0.47687M -0.47687M 0.03M 0.01M -0.02444M
Net borrowings -0.05472M -0.05472M -0.05472M -0.06500M -0.13500M
Total cash from financing activities 0.01M 41.18M 12.40M 7.40M 2.05M
Change to operating activities -0.84799M 0.21M -0.10099M -0.02729M 0.03M
Net income -19.97956M -14.90391M -8.16359M -4.69764M -2.71840M
Change in cash -0.00414M 28.38M 5.52M 3.51M -0.13507M
Begin period cash flow 0.04M 9.12M 3.60M 0.09M 0.23M
End period cash flow 0.03M 37.50M 9.12M 3.60M 0.09M
Total cash from operating activities -0.01609M -12.80737M -6.90978M -3.90733M -2.16043M
Issuance of capital stock 0.01M 59.87M 12.40M 7.47M 2.18M
Depreciation 0.13M 0.13M 0.13M 0.13M -
Other cashflows from investing activities - - - - -
Dividends paid 0.00000M 0.00000M - - -
Change to inventory - 0.00000M 0.18M -0.03036M 0.07M
Change to account receivables 0.00724M -0.09232M 0.21M -0.31548M -0.04368M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.05M 0.03M 0.03M 0.01M 0.07M
Change to netincome 3.19M 0.87M 4.46M 0.70M 0.76M
Capital expenditures 0.00030M 0.48M 0.48M 0.48M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.72M 1.23M - - -
Stock based compensation 3.19M 1.46M - - -
Other non cash items 15.92M -0.59439M 8.16M 4.70M 2.72M
Free cash flow -0.01639M -12.80737M -6.91028M -3.90733M -0.02444M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IXHL
Incannex Healthcare Ltd ADR		 0.01 0.33% 3.06 - - 68.43 2.51 98.98 -2.4351
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Hea

Incannex Healthcare Ltd ADR

8 Century Circuit, Sydney, NSW, Australia, 2153

Key Executives

Name Title Year Born
Mr. Joel Bradley Latham MD, CEO & Exec. Director 1990
Mr. Madhukar Bhalla CFO & Company Sec. 1959
Mr. Lekhram Changoer M.Sc. Chief Technical Officer 1967
Dr. Mark Bleackley Chief Scientific Officer, Head of Programs & Member of the Advisory Board NA
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Exec. Officer of IncannexTM NA
Ms. Rosemarie Walsh VP of Clinical Operations & Member of the Advisory Board NA
Mr. Joseph Swan Head of Fin. NA
Mr. Joel Bradley Latham MD, CEO & Executive Director 1990
Mr. Joseph Swan CFO, Treasurer & Secretary 1992
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Executive Officer of IncannexTM NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions